Recent Press Releases

PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015

BEDMINSTER, N.J.--NPS Pharmaceuticals, Inc. (NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today reported that...

Raptor Pharmaceutical Inc. (RPTP) Announces Management Changes

Raptor Pharmaceutical Inc. (RPTP) Announces Management Changes NOVATO, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its...

AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. As CEO

AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. As CEO BOSTON, Oct. 23, 2014 /PRNewswire/ -- AbVitro Inc., a therapeutic target discovery company, announced that Jeffrey M. Ostrove, Ph.D. has been...

IMPAX Laboratories, Inc. (IPXL) Announces Departure Of Carole Ben-Maimon, M.D., President Of Global Pharmaceuticals

IMPAX Laboratories, Inc. (IPXL) Announces Departure Of Carole Ben-Maimon, M.D., President Of Global Pharmaceuticals HAYWARD, Calif., Oct. 22, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ:...

Cardio3 BioSciences Appoints Dr. Warren Sherman As Chief Medical Officer

Cardio3 BioSciences Appoints Dr. Warren Sherman As Chief Medical Officer MONT-SAINT-GUIBERT, Belgium, October 23, 2014 /PRNewswire/ -- Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD),...

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD To Board Of Managers

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD To Board Of Managers KALAMAZOO, Mich., Oct. 23, 2014 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced...

Synchrogenix Appoints Two New Global Submissions Directors

Synchrogenix Appoints Two New Global Submissions Directors WILMINGTON, Del., Oct. 23, 2014 /PRNewswire/ -- Synchrogenix Information Strategies Inc., a regulatory writing company headquartered in...

Eleven Biotherapeutics (EBIO) Appoints Wendy L. Dixon, PhD To Board Of Directors

Eleven Biotherapeutics (EBIO) Appoints Wendy L. Dixon, PhD To Board Of Directors Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to...

Leading Researchers Join Biogen Idec (BIIB) To Advance Drug Discovery For Neurodegenerative Diseases

Leading Researchers Join Biogen Idec (BIIB) To Advance Drug Discovery For Neurodegenerative Diseases CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that two leading...

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of...

Liftstream Report Finds Ten Men for Every Woman Present in Biotech Boardrooms

Unstructured hiring practices and over-reliance on personal networks is limiting opportunities for women in biotech Germany and The Netherlands have the lowest proportion of women in the boardroom...

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments Reserved capital increased with €30 million, of...

Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin -- Relamorelin is a Novel Peptide Ghrelin Agonist for Diabetic Gastroparesis ---- Actavis Option to...

Forendo Pharma closes EUR 12 million Series A financing round to develop a novel targeted therapy for endometriosis

Turku, Finland--Forendo Pharma today announced the successful closing of a EUR 12 million new investment round. Novartis Venture Fund and MS Ventures will participate in the financing round,...

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine Published: Oct 23, 2014 (Thomson Reuters ONE via...

LEADING RESEARCHERS JOIN BIOGEN IDEC TO ADVANCE DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

–Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort– CAMBRIDGE, Mass., October 23, 2014, Biogen Idec (NASDAQ: BIIB)...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

INDIANAPOLIS and VANCOUVER, British Columbia -- Eli Lilly and Company (NYSE: LLY) and Zymeworks Inc. today announced the expansion of their existing licensing and collaboration agreement. Originally...

Johnson & Johnson Innovation Announces New J-Labs Incubator at Texas Medical Center

J-Labs @TMC Will Be a Core Component of the Texas Medical Center's Innovation Institute HOUSTON, October 23, 2014 -- Johnson & Johnson Innovation, LLC., today announced plans to expand...

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Deal Expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014...